SOURCE: Alliant Diagnostics, Inc.

June 05, 2007 10:30 ET

Alliant Diagnostics, Inc. Provides Revenue Guidance for 1st Quarter 2007

BOCA RATON, FL--(Marketwire - June 5, 2007) - Alliant Diagnostics, Inc. (PINKSHEETS: ALNA), a rapidly growing provider of hiring management services, announced today that first quarter revenues for 2007 on an unaudited basis will be approximately $880,000, which would represent an increase of six percent year over year. The Company's first quarter net income loss was estimated to be approximately $131,000 compared with a loss of $98,620 in the previous fiscal year's first quarter.

Primary fiscal 1st quarter 2007 financial guidance assumptions highlights include:

--  Gross profit margin increased approximately 16% from 2006 Q1 to 2007
    Q1
--  Administrative Expenses increased approximately 15% from 2006 Q1 to
    2007 Q1
--  Net income losses widened approximately 33% 2006 Q1 to 2007 Q1
--  56 new accounts established to an estimated 1000 total active accounts
    
The Company reported that increases in losses were primarily related to the addition of new personnel and IT expenses. Increases in staffing for sales and accounting departments over the last several months were incurred. The Company's capital expenditures related to software and computer hardware investments for new product offerings added substantial expenses as well.

The Company also noted that at the end of March, the Company initiated several cost-cutting measures to attempt to reach profitability within the coming months. These cuts were primarily related to sales and accounting personnel. Additionally, several marketing-related expenses were curtailed.

"First quarter marked our best revenue period in Alliant's history. By increasing profit margins and reducing expenses, we believe the company is better positioned than ever before to leverage its services in the marketplace," said Jesse Berger, CFO of Alliant Diagnostics, Inc.

About Alliant Diagnostics, Inc.

Alliant Diagnostics provides background checks and drug tests to employers who want fast, cost-effective, and compliant screening services. Alliant Diagnostics combines multiple service offerings, technology, and industry expertise to help companies develop best-practice screening solutions and manage the employee life cycle. Our specialty is helping companies create prescreening solutions that save time and money. Our web-enabled technology and FCRA compliant processes ensure that clients receive improved turnaround times, hire the best candidates, reduce legal risks and maximize financial savings.

This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release, including, without limitation, statements under "Risk Factors" and "Business" regarding our anticipated financial position, business strategy and plans and objectives of our management for future operations, are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "estimate," "plans," "expect," "intend" and similar expressions, as they relate to Alliant or our management, identify forward-looking statements. Any forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to our management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as those disclosed below, including, but not limited to, our plans to develop our products and develop sales, marketing, finance and administrative functions, dependence on major clients, competitive factors and pricing pressures, changes in legal and regulatory requirements, general economic conditions and our planned use of the proceeds of this Offering. Any forward-looking statements reflect our current views with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this paragraph.

Contact Information